Dysmenorrhea Treatment MarketOverview:
According to a recent study by Market ResearchCommunity, the therapies for dysmenorrheatreatment market is predicted to growfrom USD XX billion in 2021 to USD XX billion in 2030.
Cramping during a period causes excruciatingagony that radiates from the lower abdomen to the back, this, and the legs.
About five years following the start of their menstrual cycle, many women start
experiencing dysmenorrhea—agonizing pain—during the first few years of
adolescence. Dysmenorrhea treatment is the name of the therapy utilised to
address the issue.
North America, Europe, Asia-Pacific, and LatinAmerica are the four regions into which the market is divided. Over the
forecast period of 2022–2030, the market for treatments for dysmenorrhea is
anticipated to grow significantly, with a CAGR of about 8.3%. This is despite a
significant decline in product sales during the initial stages of pandemic spread
and the implementation of lockdown regulations across the globe.
The report includesa regional analysis and country analysis with the latest trends, along with the
major key players including Novartis AG, Bayer AG, Abbott Laboratories, F.
Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC, Focus Consumer
Healthcare, Johnson & Johnson, and Alvogen.
The global prevalence of disorderssuch as endometriosis, the primary cause of secondary dysmenorrhea, is
increasing. Endometriosis affects an estimated 1 in 10 women throughout their
fertile years, or around 176 million people globally, according to an article
titled "Understanding Endometriosis—the Basics" published in July 2021.
This element is predicted to have a substantial influence on market growth. As
a result of the aforementioned factors, the nonsteroidal anti-inflammatory
medicine category is predicted to considerably contribute to market expansion.
North America is dominate the growthof the dysmenorrhea treatment market owing to the introduction of innovative
products for treating the discomfort associated with primary and secondary
dysmenorrhea. For example, in 2021, Pfizer Inc. and Myovant Sciences received
FDA authorization for the assessment of a supplementary Novel Drug Application
(sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone
acetate 0.5 mg) to treat mild to severe endometriosis pain. As a result of
these reasons, the market for dysmenorrhea therapy in the United States is
predicted to increase considerably over the forthcoming years.
The study is consolidated into major segments and further into sub-segments,such as by Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), by Treatment Type
(Non-steroidal Anti-inflammatory Drugs (NSAIDs), HormonalTherapy)to forecast the size by dysmenorrheatreatment market value; also includes the analysis of past market dynamics from 2016 – 2021,considering 2021 as the base year.
Contact us:
Market Research Community
